Ahmad SM,Borch TH,Hansen M,Andersen MH M .2016 .PD-L1-specific T cells. Cancer Immunol, 65(7) : 797-804.
Almatroudi A .2022 .The incidence rate of esophageal cancer in Saudi Arabia: An observational and a descriptive epidemiological analyses. Front. Public Health, 10 : 818691.
Brandt K,Grünler J,Brismar K,Wang J .2015 .Effects of IGFBP-1 and IGFBP-2 and their fragments on migration and IGF-induced proliferation of human dermal fibroblasts. Growth Horm. IGF Res., 25(1) : 34-40.
Ely S,Alabaster A,Dominguez DA,Maxim C,Ashiku SK,Patel AR,Velotta JB .2023 .Effect of thoracic surgery regionalization on 1- and 3-year survival after cancer esophagectomy. Ann Surg., 277(2) : e305-e312.
Espelund U,Renehan AG,Cold S,Oxvig C,Lancashire L,Su Z,Flyvbjerg A,Frystyk J .2018 .Prognostic relevance and performance characteristics of serum IGFBP-2 and PAPP-A in women with breast cancer: A long-term Danish cohort study. Cancer Med, 7(6) : 2391-2404.
Ferlay J,Colombet M,Soerjomataram I,Mathers C,Parkin DM,Piñeros M,Znaor A,Bray F A .2019 .Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 144(8) : 1941-1953.
Gao L,Zhang A .2023 .Copper-instigated modulatory cell mortality mechanisms and progress in oncological treatment investigations. Front. Immunol., 14 : 1236063.
Garrett-Thomson SC,Massimi A,Fedorov EV,Bonanno JB,Scandiuzzi L,Hillerich B,Seidel RD,Love JD,Garforth SJ,Guha C,Almo SC C .2020 .Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex. PLoS One, 15(6) : e0233578.
Guiot J,Njock MS,André B,Gester F,Henket M,de Seny D,Moermans C,Malaise MG,Louis R .2021 .Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction. Sci. Rep, 11(1) : 10882.
He J,Pan Y,Guo Y,Li B,Tang Y .2020 .Study on the expression levels and clinical significance of PD-1 and PD-L1 in plasma of NSCLC patients. J. Immunother., 43(5) : 156-164.
Kaur G,Balasubramaniam SD,Lee YJ .2020 .IGFBP-2 in cervical cancer development. Exp. Mol. Pathol, 113 : 104362.
Kawasaki K,Noma K,Kato T,Ohara T,Tanabe S,Takeda Y,Matsumoto H,Nishimura S,Kunitomo T,Akai M,Kobayashi T,Nishiwaki N,Kashima H,Maeda N,Kikuchi S,Tazawa H,Shirakawa Y,Fujiwara T Y .2023 .PD-L1-expressing cancer-associated fibroblasts induce tumor immunosuppression and contribute to poor clinical outcome in esophageal cancer. Cancer Immunol, 72(11) : 3787-3802.
Luebeck EG,Curtius K,Jeon J,Hazelton WD .2013 .Impact of tumor progression on cancer incidence curves. Cancer Res., 73(3) : 1086-1096.
Nachiappan M. Kapoor VK .2022 .Esophageal Cancer: Whether and What Before or After Surgery? Indian J Surg Oncol. , 13(4) : 880-887.
Nirmal AJ,Maliga Z,Vallius T,Quattrochi B,Chen AA,Jacobson CA,Pelletier RJ,Yapp C,Arias-Camison R,Chen YA,Lian CG,Murphy GF,Santagata S,Sorger PK .2022 .The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution. , 12(6) : 1518-1541.
Strong VE,D'Amico TA,Kleinberg L,Ajani J .2013 .Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J. Natl. Compr. Canc. Netw., 11(1) : 60-66.
Sun G,Chen J,Liang J,Yin X,Zhang M,Yao J,He N,Armstrong CM,Zheng L,Zhang X,Zhu S,Sun X,Yang X,Zhao W,Liao B,Pan X,Nie L,Yang L,Chen Y,Zhao J,Zhang H,Dai J,Shen Y,Liu J,Huang R,Liu J,Wang Z,Ni Y,Wei Q,Li X,Zhou Q,Huang H,Liu Z,Shen P,Chen N,Zeng H N .2021 .Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat. Commun, 12(1) : 5262.
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Bray F A .2020 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Global cancer statistics, 71(3) : 209-249.
Van den Heuvel M,Holdenrieder S,Schuurbiers M,Cigoianu D,Trulson I,van Rossum H,Lang D H .2024 .Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies. Tumour. Biol, 46 : S233-s268.
Vocka M,Langer D,Fryba V,Petrtyl J,Hanus T,Kalousova M,Zima T,Petruzelka L T .2019 .Novel serum markers HSP60, CHI3L1 and IGFBP-2 in metastatic colorectal cancer. Oncol. Lett., 18(6) : 6284-6292.
Wang Y,Yang W,Wang Q. Zhou Y .2023 .Mechanisms of esophageal cancer metastasis and treatment progress. Front Immunol, 14 : 1206504.
Wlodarczyk B,Durko L,Wlodarczyk P,TalarWojnarowska R,Malecka-Wojciesko E .2023 .9 but Not IGF-1/IGFBP-2 is a useful biomarker for pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP) differentiation. J. Clin. Med, 12(12) : 3762-3772.
Yuan J,Sun Y,Wang K,Wang Z,Li D,Fan M,Bu X,Chen J,Wu Z,Geng H,Wu J,Xu Y,Chen M,Ren H M .2022 .Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction. BMC Cancer, 22(1) : 686.
Zhang H,Li H,Zhang Q,Wang Z,Yang Y .2023 .Metallothionein in tumor progression and drug resistance: Emerging roles and therapeutic potential. cancers (Basel), 15(4) : 1011.
Zheng H,Liu H,Li H,Dou W,Wang J,Zhang J,Liu T,Wu Y,Liu Y,Wang X Y .2022 .Characterization of stem cell landscape and identification of stemnessrelevant prognostic gene signature to aid immunotherapy in colorectal cancer. Stem Cell Res. Ther., 13(1) : 244.
Zhu D,Xu R,Huang X,Tang Z,Tian Y,Zhang J,Zheng X .2021 .Cell Death Differ. , 28(6) : 1773-1789.